Cargando…

CD90 determined two subpopulations of glioma-associated mesenchymal stem cells with different roles in tumour progression

Human glioma-associated mesenchymal stem cells (gbMSCs) are the stromal cell components that contribute to the tumourigenesis of malignant gliomas. Recent studies have shown that gbMSCs consist of two distinct subpopulations (CD90(+) and CD90(−) gbMSCs). However, the different roles in glioma progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qing, Yi, Dong-Ye, Xue, Bing-Zhou, Wen, Wan-Wan, Lu, Yin-Ping, Abdelmaksou, Ahmed, Sun, Min-xuan, Yuan, De-tian, Zhao, Hong-Yang, Xiong, Nan-Xiang, Xiang, Wei, Fu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204133/
https://www.ncbi.nlm.nih.gov/pubmed/30368520
http://dx.doi.org/10.1038/s41419-018-1140-6
Descripción
Sumario:Human glioma-associated mesenchymal stem cells (gbMSCs) are the stromal cell components that contribute to the tumourigenesis of malignant gliomas. Recent studies have shown that gbMSCs consist of two distinct subpopulations (CD90(+) and CD90(−) gbMSCs). However, the different roles in glioma progression have not been expounded. In this study, we found that the different roles of gbMSCs in glioma progression were associated with CD90 expression. CD90(high) gbMSCs significantly drove glioma progression mainly by increasing proliferation, migration and adhesion, where as CD90(low) gbMSCs contributed to glioma progression chiefly through the transition to pericytes and stimulation of vascular formation via vascular endothelial cells. Furthermore, discrepancies in long non-coding RNAs and mRNAs expression were verified in these two gbMSC subpopulations, and the potential underlying molecular mechanism was discussed. Our data confirm for the first time that CD90(high) and CD90(low) gbMSCs play different roles in human glioma progression. These results provide new insights into the possible future use of strategies targeting gbMSC subpopulations in glioma patients.